Literature DB >> 3997232

Treatment of malignant pheochromocytoma with combination chemotherapy.

H R Keiser, D S Goldstein, J L Wade, F L Douglas, S D Averbuch.   

Abstract

Three patients with rapidly progressive, disseminated malignant pheochromocytoma were treated with a combination chemotherapeutic regimen consisting of cyclophosphamide, vincristine, and dacarbazine in repeated 21- to 28-day cycles. All three patients had a marked decrease in blood pressure and an improvement in performance status within the first few cycles of treatment. At a follow-up of 6 to 13 months all patients continue to receive chemotherapy with further regression of tumor in two and stable disease in one. Their blood pressure is normal with minimal or no antiadrenergic therapy. Therapy has been well tolerated; moderate reversible granulocytopenia, neurotoxicity, and one episode of pneumonitis have been the major toxicities encountered. Thus, combination chemotherapy appears to be effective for symptomatic malignant pheochromocytoma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3997232     DOI: 10.1161/01.hyp.7.3_pt_2.i18

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  16 in total

1.  Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience.

Authors:  Montserrat Ayala-Ramirez; Lei Feng; Mouhammed A Habra; Thereasa Rich; Paxton V Dickson; Nancy Perrier; Alexandria Phan; Steven Waguespack; Shreyaskumar Patel; Camilo Jimenez
Journal:  Cancer       Date:  2011-10-17       Impact factor: 6.860

2.  Case report of metastatic familial pheochromocytoma treated with cisplatin and 5-fluorouracil.

Authors:  V Srimuninnimit; G L Wampler
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 3.  Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress.

Authors:  Paola Jimenez; Claudio Tatsui; Aaron Jessop; Sonali Thosani; Camilo Jimenez
Journal:  Curr Oncol Rep       Date:  2017-10-28       Impact factor: 5.075

Review 4.  Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options.

Authors:  Svenja Nölting; Ashley Grossman; Karel Pacak
Journal:  Exp Clin Endocrinol Diabetes       Date:  2018-09-20       Impact factor: 2.949

5.  Controlling Tumor Progression with Cyclophosphamide, Vincristine, and Dacarbazine Treatment Improves Survival in Patients with Metastatic and Unresectable Malignant Pheochromocytomas/Paragangliomas.

Authors:  Shiko Asai; Takuyuki Katabami; Mika Tsuiki; Yasushi Tanaka; Mitsuhide Naruse
Journal:  Horm Cancer       Date:  2017-01-20       Impact factor: 3.869

Review 6.  Metastatic paraganglioma.

Authors:  Stephanie M J Fliedner; Hendrik Lehnert; Karel Pacak
Journal:  Semin Oncol       Date:  2010-12       Impact factor: 4.929

Review 7.  [Drug therapy of endocrine neoplasms. Part I: Thyroid neoplasms, adrenal neoplasms and parathyroid neoplasms].

Authors:  M Schott; W A Scherbaum; J Feldkamp
Journal:  Med Klin (Munich)       Date:  2000-01-15

8.  Malignant pheochromocytoma with IVC thrombus.

Authors:  Katsumi Shigemura; Kazushi Tanaka; Soichi Arakawa; Isao Hara; Gaku Kawabata; Masato Fujisawa
Journal:  Int Urol Nephrol       Date:  2007       Impact factor: 2.370

Review 9.  Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma.

Authors:  Camilo Jimenez; Eric Rohren; Mouhammed Amir Habra; Thereasa Rich; Paola Jimenez; Montserrat Ayala-Ramirez; Eric Baudin
Journal:  Curr Oncol Rep       Date:  2013-08       Impact factor: 5.075

Review 10.  Treatment of malignant pheochromocytoma.

Authors:  R Adjallé; P F Plouin; K Pacak; H Lehnert
Journal:  Horm Metab Res       Date:  2009-08-11       Impact factor: 2.936

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.